Главная › Колоректальный рак › Пенсильвания › Pittsburgh
Клинические исследования Колоректальный рак в городе Pittsburgh, PA
32 исследований по теме Колоректальный рак ищут участников в центрах в городе Pittsburgh и поблизости (в радиусе около 30 миль). Откройте исследование, чтобы узнать критерии участия и контакты исследовательской группы.
Официальный текст исследования (на английском)
Ищете участников для исследования? Разместите его вверху страницы — $99 на 30 дней →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Набор участниковФаза 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
Набор участниковФаза 2
- Allegheny General Hospital, Pittsburgh
- West Penn Hospital, Pittsburgh
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Набор участниковФаза 1
- Exelixis Clinical Site #32, Pittsburgh
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Набор участниковФаза 1
- Research Site, Pittsburgh
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
Набор участниковФаза 1
- UPMC Hillman Cancer Center, Pittsburgh
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Набор участниковФаза 1/2
- University of Pittsburgh Medical Center (UPMC), Pittsburgh
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Набор участниковФаза 3
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center, Pittsburgh
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Набор участниковФаза 1
- Research Site, Pittsburgh
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Набор участниковФаза 3
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center, Pittsburgh
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Набор участниковФаза 3
- Allegheny General Hospital, Pittsburgh
- West Penn Hospital, Pittsburgh
- Jefferson Hospital, Jefferson Hills · 11 миль отсюда
- и еще 2
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Набор участниковФаза 2/3
- Local Institution - 0604, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Набор участниковФаза 1
- University of Pittsburgh Medical Center, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Набор участниковФаза 1/2
- Allegheny Health Network, Pittsburgh
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Набор участниковФаза 3
- Allegheny General Hospital Cancer Institute, Pittsburgh
- Hillman Cancer Center, Pittsburgh
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
Набор участниковФаза 1
- UPMC Hillman Cancer Center, Pittsburgh
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Набор участниковФаза 3
- Clinical Study Site, Pittsburgh
- Clinical Study Site, Pittsburgh
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
Набор участниковФаза 2
- UPMC / University of Pittsburgh Medical Center, Pittsburgh
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Набор участниковФаза 1/2
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Набор участниковФаза 1
- University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center, Pittsburgh
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Набор участниковФаза 2
- UPMC Hillman Cancer Center, Pittsburgh
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Набор участниковФаза 1/2
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
Набор участниковФаза 1
- UPMC Hillman Cancer Center, Pittsburgh
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Набор участниковФаза 1/2
- UPMC Hillman Cancer Center, Pittsburgh
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Набор участниковФаза 3
- UPMC Hillman Cancer Center - St Margarets, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC Hillman Cancer Center - Passavant (HOA), Pittsburgh
- и еще 6
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Набор участниковФаза 1
- University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Набор участниковФаза 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Anastomotic Safety and Surveillance Using Real-time Enhanced Sensing Using xBar
Набор участников
- Allegheny Health Network, Pittsburgh
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Набор участниковФаза 1
- University of Pittsburg Medical Center (UPCM), Pittsburgh
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Набор участниковФаза 1
- UPMC Hillman Cancer Center, Pittsburgh
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
Набор участниковФаза 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
Набор участников
- AHN West Penn Hospital, Pittsburgh
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Набор участниковФаза 1
- UPMC Hillman Cancer Center, Pittsburgh
Исследования Колоректальный рак в других городах
- Houston, TX102 исследований
- New York City, NY78 исследований
- Nashville, TN69 исследований
- Boston, MA63 исследований
- Los Angeles, CA59 исследований
- Arlington, VA52 исследований
- St. Louis, MO50 исследований
- San Antonio, TX46 исследований
- Philadelphia, PA44 исследований
- Grand Rapids, MI40 исследований
- Baldwin Park, CA37 исследований
- Chicago, IL34 исследований
Другие исследования в городе Pittsburgh
- Немелкоклеточный рак легкого48 исследований
- Рак (все виды)41 исследование
- Рак молочной железы39 исследований
- Метастатический рак31 исследование
- Меланома31 исследование
- Рак яичников30 исследований
- Рак эндометрия23 исследований
- Рак простаты23 исследований
- Рак легких23 исследований
- Плоскоклеточный рак головы и шеи22 исследований
- Инсульт22 исследований
- Депрессия22 исследований
Источник: ClinicalTrials.gov, данные получены 6 окт. 2026 г.. Каждая исследование устанавливает свои критерии участия; решение о включении принимает исследовательская группа.